ClinicalTrials.gg
CompletedNCT02689115NUIRAUpdated Feb 23, 2016

NFKB1 and IKK Epsilon in Rheumatoid Arthritis

An observational study in Rheumatoid Arthritis, sponsored by Asociación Científica Latina A.C.. Completed. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-02-23.

Sponsored by Asociación Científica Latina A.C. · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
60
Ages
30 Years to 65 Years
Sex
All
01

Study summary

Rheumatoid arthritis (RA) is a systemic and auto-immune disorder whose primary characteristic is the chronic inflammation of joints. The objective of this study was to evaluate whether there was an association between the NF-KB1/IKK epsilon genetic expression and the clinical activity in RA.

60 RA patients were included in the study, 30 with clinical activity and 30 with clinical remission The NF-KB1/IKK epsilon genetic expression was performed by real time quantitative Polymerase chain reaction (qPCR) through the Pfaffl method of relative quantification with Taqman probes.

Read the detailed description

Patients with a confirmed diagnosis of RA were allocated in two groups based on the Disease Activity Score 28 (DAS28): a) with clinical activity and b) with clinical remission. Key exclusion criteria were patients with any other inflammatory or autoimmune disease and patients with infections. The control group was represented by healthy patients Sample size

The sample size calculation was carried out through the following formula:

n= Nz2 pq /d2(N-1) +z2 pq With N=30, Z=2.46 (99% of confidence), p=0.9, q=0.1, d=0.05 (95% of accuracy). The sample size contained 20 patients with RA.

Anthropometric measurements Weight (kg) and height (m) were calculated in a mechanical column scale (SECA). The patients were classified according to their Body mass index (BMI, weight (Kg)/ height (m)2) as a) normal weight (BMI\< 24.9), b) overweight (24.9 kg/m2 \<BMI\<29.9 kg/m2) and c) obese (BMI> 30 kg/m2).

Lymphocyte extraction Lymphocytes from peripheral blood were extracted using the ACK Lysing Buffer® (Life technologies, Grand Island, NY) kit. Briefly, a venous blood sample in EDTA tube (BD Vacutainer®, Franklin Lakes, NJ), was centrifuged at 3500 rpm during 5-8 minutes. The resulting intermediate white colored phase was extracted and placed in an eppendorf tube; 1 mL of ACK Lysing Buffer® was added and carefully re-suspended. Once again, the suspension was centrifuged at 3500 rpm during 5-8 minutes and the supernatant was discarded. This last step was repeated until the leukocyte package was completely white. Finally, it was added 100 mcl of ACK Lysing Buffer® and frozen at -70ºC for later use.

Genetic expression From the leukocyte package (approximately 10 to 15 mg), it was performed a messenger RNA (mRNA) extraction using the Magna Pure LC RNA isolation kit III (Roche) in the Magna Pure LC 2.0 Instrument. The A260/A280 nm absorbance ratio was >1.8 (quality) and total RNA concentration was calculated by determining absorbance at 260 nm established with the NanoPhotometer (Implen GmbH, Germany) and the extracts were adjusted to a concentration of 20 µg of DNA for the PCR reaction.

Subsequently, the cDNA was synthesized with the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Applied Science). It was performed a real time polymerase chain reaction (qPCR), using the specific primers and probes for NF-KB1, IKK epsilon and 18s (as constitutive gene), using a 7500 Fast Real Time PCR System (Applied Biosystems, Applera UK, Cheshire, UK), mixing TaqMan® Universal PCR Master Mix and the specific probes for each gene NF-KB1 (Hs00765730-m1), IKK epsilon (Hs01063858-m1) and 18S (Hs99999901-s1), (Applied Biosystems, Applera UK, Cheshire, UK).

According to the Ct obtained from the two different groups it was calculated the relative units of expression through the Pfaffl relative quantification method, in which it was used as control a healthy patient.

Statistical analysis The statistical analysis was performed through the Sigmaplot software version 12.0. Parametric and non-parametric test were used in function to the variable distribution: among the parametric test that were performed to compare the groups, the Student´s T-test was included; the non-parametric tests applied were: The Mann-Whitney U test and the Shapiro-Wilk test. Finally, a receiver operating characteristic (ROC) was used for the analysis of the genetic expression of NF-KB1/IKK epsilon with the SPSS software version 22.0.

02

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Nuclear factor Kappa B
  • IKK epsilon
03

In context

Arthritis, Rheumatoid

2,963 studies on the registry are indexed under Arthritis, Rheumatoid; 396 are open to participants now.

This study's enrollment of 60 is below the median of 176 across 854 observational studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

Asociación Científica Latina A.C. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The key inclusion criteria were patients with RA who met the criteria established by the American College of Rheumatology (ACR). Two groups were conformed based on the Disease Activity Score 28 (DAS28): a) with clinical activity (DAS28 > 3.6) and b) with clinical remission (DAS28 \< 2.4). Key exclusion criteria were patients with any other inflammatory, autoimmune or neoplastic disease and patients with infections. The control group was represented by healthy patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis criteria established by the American College of Rheumatology (ACR).

Exclusion criteria

Exclusion Criteria:

  • Patients with any other inflammatory, autoimmune or neoplastic disease and patients with infections.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
60 participants (actual)
Patient registry
No

Groups and cohorts

  • Clinical activity

    Patients with rheumatoid arthritis who met the criteria established by the American College of RheumatologyDisease Activity Score 28 (DAS28) \> 3.6.

    Other: Genetic relative expression

  • Clinical remission

    Patients with rheumatoid arthritis with Disease Activity Score 28 (DAS28) \< 2.4.

    Other: Genetic relative expression

Interventions

  • OtherGenetic relative expression

    The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.

06

What researchers measure

Primary outcomes

  1. Relative genetic expression of NF-KB1 and IKK epsilon.

    Time frame: Within one month after the patient selection.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Jun 2014 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2016
First posted
Feb 23, 2016
Start
Nov 2013
Primary completionActual
Jun 2014
CompletionActual
Dec 2015
Last update
Feb 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02689115
Lead sponsor
Asociación Científica Latina A.C.
Collaborators
Universidad Autonoma del Estado de Mexico
Responsible party
Sponsor
First posted
Feb 23, 2016
Start date
Nov 2013
Primary completion
Jun 2014
Completion
Dec 2015
Last update
Feb 23, 2016

Study contacts

Hugo Mendieta Zerón, PhD.
study director · Asociación Científica Latina A.C.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion